Amicus Therapeutics Announces FDA Approval And Launch Of New Treatment For Pompe Disease
Portfolio Pulse from Benzinga Newsdesk
Amicus Therapeutics (NASDAQ:FOLD) has received FDA approval for its two-component therapy, Pombiliti and Opfolda, for adults with late-onset Pompe disease. The approval is based on data from the Phase 3 PROPEL study. The company plans to immediately launch the treatment in the U.S. The therapy has also been approved in the European Union and the United Kingdom.
September 28, 2023 | 2:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amicus Therapeutics has received FDA approval for its new treatment for late-onset Pompe disease, which could potentially increase the company's revenues and market share in the rare disease treatment sector.
The FDA approval of a new treatment typically leads to increased revenues for the company, as it allows the company to sell the treatment in the market. This could potentially increase Amicus Therapeutics' market share in the rare disease treatment sector, as the treatment is for a rare disease with limited treatment options. The immediate launch of the treatment in the U.S. could also lead to a quick increase in revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100